SARS-CoV-2 - Dapaglifozine - Therapeutic Candidates

SARS-CoV-2 - Dapaglifozine - Therapeutic Candidates


Dapaglifozine, marketed under the name Forxiga®, is an anti-diabetic drug in the glifozin class. It is a SGLT-2 transporter inhibitor that reduces glycated hemoglobin, leads to weight loss and improves blood pressure in patients with type 2 diabetes. Dapaglifozine may be given alone or in combination with insulin, an antihyperglycemic agent, depending on the degree of diabetes.
Since the start of the Covid-19 pandemic, physicians have observed that some patients are at increased risk of developing serious complications that could lead to death. One of the factors that may increase this risk are cardiometabolic diseases such as hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, and heart and kidney failure. Since inhibitors of SGLT-2 transporters have shown strong protective effects on the heart and kidneys in patients with type 2 diabetes, dapaglifozine could protect these vital organ systems in Covid-19.

Search result : 251 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 88
  • [3H] 2
  • Biochemicals 145
  • Inhibitor/Antagonist/Agonist 98
  • Buffers and reagents 6
  • Radiochemicals 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
A5854-100mg
 100mg 
AOB87300-5
 5mg 
T2389-100mg
 100mg 
T2389-200mg
 200mg 
T2389-1mL
 1mL 
T2389-10mg
 10mg 
T2389-50mg
 50mg 
T2389-2mg
 2mg 
T2389-5mg
 5mg 
T2389-25mg
 25mg 
T10957-100mg
 100mg 
HY-10450-5mg
 5mg 
HY-10450-1ml
 10mM/1mL 
HY-10450-10mg
 10mg 
HY-10450-100mg
 100mg